# **A Prospective Cohort Study providing Insights for Markers of Adverse Pregnancy Outcome in Women of Advanced Maternal Age**

Samantha C. LEAN, Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester, UK. sl961@cam.ac.uk

Rebecca L. JONES, Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester, UK. rebecca.lee.jones@manchester.ac.uk

Stephen A. ROBERTS, Centre for Biostatistics, Faculty of Biology, Medicine and Health, University of Manchester, UK. steve.roberts@manchester.ac.uk

Alexander E.P. HEAZELL, Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester, UK

****

**Supplementary Figure 3: Circulating concentrations of placental hormones in women of advanced maternal age with normal and adverse pregnancy outcome,** n=43/group. Maternal serum/plasma at 28 weeks (A, C, E) and 36 weeks (B, D, F) gestation against pregnancy outcome. A-B) hCG, C-D) PAPP-A, E-F) Progesterone. Data are median, IQR and absolute range, Mann Whitney U.